S&P 500 Futures
(0.06%) 5 209.75 points
Dow Jones Futures
(0.21%) 39 077 points
Nasdaq Futures
(-0.12%) 18 175 points
Oil
(-0.18%) $78.34
Gas
(-0.36%) $2.19
Gold
(-0.39%) $2 322.00
Silver
(-0.63%) $27.44
Platinum
(-0.24%) $962.55
USD/EUR
(0.08%) $0.929
USD/NOK
(0.37%) $10.86
USD/GBP
(0.22%) $0.798
USD/RUB
(-0.30%) $91.07

Actualizaciones en tiempo real para XORTX Therapeutics Inc. [XRTX]

Bolsa: NASDAQ Sector: Healthcare Industria: Biotechnology
Última actualización6 may 2024 @ 16:00

-1.85% $ 2.65

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 16:00):
Profile picture for XORTX Therapeutics Inc.

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection...

Stats
Volumen de hoy 6 761.00
Volumen promedio 52 260.00
Capitalización de mercado 47.67M
EPS $0 ( 2024-03-31 )
Próxima fecha de ganancias ( $0 ) 2024-06-27
Last Dividend $0.0750 ( 2014-01-31 )
Next Dividend $0 ( N/A )
P/E -6.46
ATR14 $0.0770 (2.93%)

XORTX Therapeutics Inc. Correlación

10 Correlaciones Más Positivas
VTYX0.922
ALXO0.895
RCM0.893
JRJC0.878
FEMY0.877
CTMX0.876
QRTEA0.875
GNTY0.873
GOEV0.872
NAKD0.87
10 Correlaciones Más Negativas
IDCC-0.895
OTEX-0.892
VBOCU-0.89
BLBD-0.888
MPRA-0.887
OVLY-0.887
NVCN-0.887
GPACU-0.886
OVID-0.886
GRBK-0.885

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

XORTX Therapeutics Inc. Finanzas

Annual 2022
Ingresos: $0
Beneficio Bruto: $0 (0.00 %)
EPS: $-0.520
FY 2022
Ingresos: $0
Beneficio Bruto: $0 (0.00 %)
EPS: $-0.520

Financial Reports:

No articles found.

XORTX Therapeutics Inc. Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

XORTX Therapeutics Inc. Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A
Information
First Dividend $0.0500 2011-08-10
Last Dividend $0.0750 2014-01-31
Next Dividend $0 N/A
Payout Date 2014-02-17
Next Payout Date N/A
# dividends 11 --
Total Paid Out $0.795 --
Avg. Dividend % Per Year 0.00% --
Score 1.61 --
Div. Sustainability Score 0
Div.Growth Potential Score 0
Div. Directional Score 0 --
Next Divdend (Est)
(2024-07-05)
$0 Estimate 0.00 %
Dividend Stability
0.04 Very Bad
Dividend Score
1.61
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield
2011 $0 0.00%
2012 $0 0.00%
2013 $0 0.00%
2014 $0 0.00%
2015 $0 0.00%
2016 $0 0.00%
2017 $0 0.00%
2018 $0 0.00%
2019 $0 0.00%
2020 $0 0.00%
2021 $0 0.00%
2022 $0 0.00%
2023 $0 0.00%
2024 $0 0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
SLVO Dividend Royal 2023-11-20 Monthly 12 10.77% 8.50
QYLD Dividend Royal 2023-11-20 Monthly 11 7.50% 8.50
PSEC Dividend Royal 2023-12-26 Monthly 21 7.04% 8.50
GAIN Dividend Royal 2023-12-04 Monthly 20 8.19% 8.50
GLDI Dividend Royal 2023-11-20 Monthly 12 7.15% 8.50
OXLC Dividend Royal 2023-12-14 Monthly 14 10.00% 8.50
OXSQ Dividend Royal 2023-12-14 Monthly 21 9.10% 8.50
HRZN Dividend King 2023-12-18 Monthly 15 6.60% 8.45
USOI Dividend Royal 2023-11-20 Monthly 8 16.70% 8.28
PFLT Dividend King 2023-11-15 Monthly 14 6.50% 8.27

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM01.50000[0 - 0.5]
returnOnAssetsTTM-1.1711.200-10.00-10.00[0 - 0.3]
returnOnEquityTTM-0.9721.500-10.00-10.00[0.1 - 1]
payoutRatioTTM0-1.00000[0 - 1]
currentRatioTTM9.440.80010.008.00[1 - 3]
quickRatioTTM9.280.80010.008.00[0.8 - 2.5]
cashRatioTTM9.151.50010.0010.00[0.2 - 2]
debtRatioTTM0.00429-1.5009.93-10.00[0 - 0.6]
interestCoverageTTM01.000-1.111-1.111[3 - 30]
operatingCashFlowPerShareTTM-5.222.00-1.741-3.48[0 - 30]
freeCashFlowPerShareTTM-5.252.00-2.63-5.25[0 - 20]
debtEquityRatioTTM0.00468-1.5009.98-10.00[0 - 2.5]
grossProfitMarginTTM01.000-3.33-3.33[0.2 - 0.8]
operatingProfitMarginTTM01.000-2.00-2.00[0.1 - 0.6]
cashFlowToDebtRatioTTM-366.221.000-10.00-10.00[0.2 - 2]
assetTurnoverTTM00.800-3.33-2.67[0.5 - 2]
Total Score-0.285

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-0.6811.000-0.1700[1 - 100]
returnOnEquityTTM-0.9722.50-7.65-10.00[0.1 - 1.5]
freeCashFlowPerShareTTM-5.252.00-1.751-5.25[0 - 30]
dividendYielPercentageTTM01.50000[0 - 0.4]
operatingCashFlowPerShareTTM-5.222.00-1.741-3.48[0 - 30]
payoutRatioTTM01.50000[0 - 1]
pegRatioTTM0.07831.500-2.810[0.5 - 2]
operatingCashFlowSalesRatioTTM01.000-2.500[0.1 - 0.5]
Total Score-2.39

XORTX Therapeutics Inc.

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico